Lipocine Inc LPCN 深 沪
等待开盘 05-18 09:30:00 美东时间
2.26
-0.070
-3.00%
华盛通- 最 高2.34
- 今 开2.29
- 成交量 5.56万股
- 最 低 2.255
- 昨 收 2.33
- 总市值 1863.20万
- 52周最高 12.37
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.81
- 委 比 -85.76%
- 总股本 824.43万
- 历史最高 340.00
- 量 比 0.45
- 振 幅 3.65%
- 历史最低 1.81
- 每 手 1
- 风险率 2.56%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Lipocine Q1 EPS $(0.54) Misses $(0.48) Estimate, Sales $119.397M Beat $162.500K Estimate
Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.48) by 12.5 percent. This is a 54.29 percent decrease over losses of $(0.35) per share from the
05-08 04:39
Lipocine Reshapes Board Leadership Amid Strategic Shift
An update from Lipocine ( ($LPCN) ) is now available. On April 16, 2026, Lipoci...
04-22 04:46
What's Going On With Lipocine Stock On Monday?
Lipocine stock rebounds after a steep drop as LPCN 1154 misses the Phase 3 endpoint, with encouraging subgroup data.
04-06 21:09
HC Wainwright & Co. Downgrades Lipocine to Neutral
HC Wainwright & Co. analyst Yi Chen downgrades Lipocine (NASDAQ:LPCN) from Buy to Neutral.
04-06 20:06
Lipocine's LPCN 1154 Misses Phase 3 Primary Endpoint in Postpartum Depression; Shows Early Efficacy Signals In Patients With Prior Psychiatric History And Maintains Favorable Safety Profile
In the Phase 3 study population (N=90) of patients with PPD, LPCN 1154 did not show a statistically significant reduction from baseline in HAM-D17 total score compared to placebo at hour 60 (primary endpoint); the
04-02 20:13
Lipocine FY 2025 revenue fell 82% to USD 1.98 million as net loss was USD 9.63 million
Lipocine FY 2025 revenue fell 82% to USD 1.98 million as net loss was USD 9.63 million Lipocine reported a FY 2025 net loss of USD 9.6 million, or USD 1.69 per diluted share, compared with net income of USD 8,352 a year earlier. FY 2025 revenue fell 82% to USD 2 million, mainly reflecting lower lice
03-10 18:13
Lipocine FY2025 revenue fell 82% to USD 1.98 million as net loss totaled USD 9.6 million
Lipocine FY2025 revenue fell 82% to USD 1.98 million as net loss totaled USD 9.6 million Lipocine reported a FY 2025 net loss of USD 9.6 million, compared with net income of USD 8,000 a year earlier. FY 2025 revenue fell 82% to USD 1.98 million, driven mainly by USD 1.5 million of license revenue an
03-10 18:03
Lipocine Reports Last Patient Last Visit in Phase 3 Trial of LPCN 1154 for Postpartum Depression
Lipocine Reports Last Patient Last Visit in Phase 3 Trial of LPCN 1154 for Postpartum Depression Lipocine Inc. reported that the last patient completed the final study visit (last patient last visit) in its pivotal Phase 3 randomized, double-blind, placebo-controlled trial of LPCN 1154 (oral brexano
02-18 21:08
